Clinical Trial Update: Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating rivaroxaban 2.5 mg twice daily in combination with aspirin for intermittent claudication in patients with peripheral arterial disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication
• Peripheral Artery Disease

Drugs mentioned

• Aspirin (Aspirin)
• Xarelto (rivaroxaban)

Snippet

Sponsor: Science Valley Research Institute | Conditions: Peripheral Artery Disease, Intermittent Claudication | Phase 4 | Status: COMPLETED